Danone: A Stabilized Stock Under Technical Pressure, Between Asian Momentum and European Anticipation

Growth Driven by a Deliberate Geographical Realignment

The third-quarter 2025 results confirm the geographical reorientation Danone has undertaken over several periods. The organic growth of 4.8% is based on a volume-mix increase of 3.2%, indicating a model less reliant on price effects than in previous quarters. This shift is mainly due to the significant contribution from the China, North Asia, and Oceania region, which posted a comparable growth of 13.8% in the third quarter, driven by a volume-mix of 15.1%. Over nine months, this region now accounts for 3.048 billion euros in revenue, representing nearly 15% of the total consolidated figure, with an organic growth of 12.1%. This pivot towards Asia partially offsets the relative slowdown in North America, which recorded only a 1.5% increase in the third quarter, with a barely positive volume-mix (+0.3%). Europe, the largest contributor in absolute terms (7.375 billion euros over nine months), grew by 2.3% on a comparable basis, a modest improvement but sufficient to stabilize the overall picture. This shifting geography highlights the group's growing reliance on still-volatile markets, where visibility remains dependent on public policies, consumption dynamics, and structurally high currency exchange risks.

Specialized Nutrition: Growth Driver Confirmed, But Not Extrapolable

The Specialized Nutrition division posted comparable growth of 8.3% in the third quarter, with a volume mix of 6.5%, reaffirming its role as the leading operational driver for the group. Over nine months, it generated 6.904 billion euros in revenue, accounting for one third of the consolidated total, with a growth of 7.5%. This momentum is fueled by infant nutrition in Asia, medical nutrition in Europe, and now, the integration of Kate Farms, whose majority stake was finalized on July 1, 2025. The announced acquisition of The Akkermansia Company on June 25, 2025, strengthens the investment strategy in next-generation probiotics, in line with the recent opening of the OneBiome Lab. These moves reflect a clear strategy: focusing investments on high-value scientific segments capable of justifying a price premium. However, this direction has a structural limitation: Specialized Nutrition continues to face stringent health regulations, long innovation cycles, and increased competition in premium segments. Thus, the current growth does not guarantee a linear extrapolation, especially if volumes stagnate or base effects normalize in Asia.

EDP and Water Divisions: Stable with No Significant Change

The Dairy and Plant-Based Products division (EDP), the largest contributor in value with 9.853 billion euros over nine months, showed a comparable growth of 3.5% in the third quarter, driven by a volume mix of 1.7%. Over nine months, the organic growth reached 3.4%, a level that confirms the stabilization of the portfolio but does not indicate any significant acceleration. The legacy brands (Activia, Actimel) continue to generate steady volumes in Europe, while plant-based alternatives struggle to offset the structural decline in certain dairy categories. The Waters division, the third largest with 3.822 billion euros over nine months, increased by 2.3% in the third quarter, with a volume mix of 1.3%. This improvement contrasts with the challenges faced in Mexico, where the category is under significant competitive and regulatory pressure. Over nine months, the organic growth of the Waters remains limited to 1.8%, with a volume mix of 0.6%, highlighting the group's difficulty in sustainably reviving an activity marked by low margins and high sensitivity to packaging and transportation costs. These two divisions ensure consistent cash flow but do not offer growth drivers likely to significantly change the group's overall trajectory.

Stock Performance and Market Analysis

Danone's stock closed at 76.98 euros on December 22, down 1% for the session after losing 0.78 euros in a sluggish market characterized by low trading volumes (0.1% of capital traded). Over the week, the stock rose by 1.16%, but it fell by 0.08% over the past seven days, indicating a technical consolidation following a 20.13% increase over the year and a 6.03% rise over the quarter. The price is now moving between a support level at 75.12 euros and resistance at 79.60 euros, within a Bollinger band ranging from 75.21 euros to 78.32 euros. The 50-day moving average stands at 77.29 euros, slightly above the current price, while the 200-day moving average (73.54 euros) confirms a medium-term upward trend. Technical indicators remain neutral: the RSI at 52 indicates neither overbought nor oversold conditions, while the MACD histogram (0.18) shows a slight upward movement without strong conviction. The Scholes signal remains neutral, consistent with a waiting phase. Analysts hold divergent positions: AlphaValue/Baader Europe raised its target from 79.70 to 80.10 euros on December 18 while maintaining a « reduce » recommendation; Bernstein remains « neutral » with an 83-euro target (November 18), and HSBC increased its target from 71 to 73 euros on November 6, keeping a « hold » position. These adjustments reflect acknowledgment of the operational trajectory, but without enough conviction to recommend strengthening positions. Additionally, the company announced two share buyback operations: a program for 3.8 million shares on December 4 to offset dilution from employee share ownership and a repurchase of 5.8 million shares held by its Spanish subsidiary on December 17, with no impact on the total amount of treasury stock. These actions, part of routine capital management, do not fundamentally alter the supply-demand balance of the stock.

Exchange Rate Guidance and Constraints: Visibility Still Conditional

Danone confirmed its 2025 targets during the third quarter release: a comparable sales growth between 3% and 5%, and an operating profit growth that outpaces sales growth. These forecasts rely on continued momentum in Asia, stabilization in Europe, and gradual improvement in North America. However, they also account for significant foreign exchange risk: the negative currency impact reached 5.1% on reported sales in the third quarter, which mechanically impacts the understanding of regional performances. The group raised 1.3 billion euros in bonds in September, divided into two tranches: 800 million euros over two years indexed to the 3-month Euribor plus 27 basis points, and 500 million euros at a fixed rate of 3.95% with a first redemption option in 2032. This issuance reflects prudent debt management but does not reduce the structural exposure to currency fluctuations, which are particularly sensitive in emerging markets. Management emphasized that the group's transformation is not complete and requires additional effort, highlighting the ongoing execution risk, especially regarding the ability to scale scientific innovations industrially and commercially.

Balancing Operational Consolidation and Structural Uncertainties

Danone's stock currently reflects an unstable balance between favorable elements—Asia's increasing prominence, sustained growth in Specialized Nutrition, and stabilization in Europe—and unresolved structural limitations: the relative stagnation in North America, low visibility in the Waters segment, persistent exposure to exchange rate effects, and the still incomplete nature of strategic transformation. Share buybacks and analyst adjustments indicate a reading of the stock based on acknowledging progress made, but lack sufficient conviction to anticipate marked acceleration. With prices between 75.12 and 79.60 euros, the stock is moving within a narrow technical range indicative of market caution. Upcoming reports need to demonstrate that Asian momentum remains sustainable, Europe continues its recovery, and North America regains visible growth. At this stage, the facts support the assertion that Danone has stabilized its operational fundamentals, but do not conclude that this stabilization alone will justify a sustainable revaluation of the stock without further proof of execution.